Lisa B. Nachtigall’s award reflects a career built around complex pituitary care
The Endocrine Society’s 2026 Vigersky Outstanding Clinical Practitioner Award went to Lisa B. Nachtigall, MD, a recognition shaped not by a single headline-making intervention, but by years of bedside work in some of endocrinology’s most demanding cases. As medical director of the Mass General Brigham Pituitary Center and associate professor of medicine at Harvard Medical School, she has built her practice around patients with pituitary disorders, especially acromegaly, where diagnosis, treatment selection, and long-term follow-up often stretch across years.
Her clinical voice is the kind patients remember. Nachtigall described the satisfaction of hearing that her words have become a mantra patients carry into daily life, a reminder that in endocrine disease, counseling can be as durable as pharmacology when the relationship is longitudinal and the diagnosis is chronic. She also pointed to the satisfaction of diagnosing functioning pituitary tumors from clinical history and watching patients improve after remission of Cushing disease or acromegaly. In this corner of medicine, the disease biology is only part of the story; symptom relief, biochemical control, and patient trust often unfold together.
Longitudinal care gives pituitary medicine its clinical weight
Pituitary disorders often demand a different tempo than many other specialties. A single visit can clarify a treatment plan, but the real value emerges over repeated encounters, when hormone excess is controlled, imaging is interpreted in context, and quality of life is tracked alongside laboratory markers. Nachtigall’s comments point to that reality without embellishment: patients with acromegaly or Cushing disease do not simply complete a course of treatment and move on. Many return for years, sometimes decades, with needs that evolve as therapies change and comorbidities accumulate.
That continuity matters because pituitary disease can be deceptively subtle at presentation. Symptoms may be attributed to more common problems for months or years before the endocrine cause becomes clear. For that reason, clinicians who can recognize the pattern from history alone remain central to outcomes. In practice, the ability to identify a functioning pituitary tumor early can reduce diagnostic delay, shorten exposure to uncontrolled hormone excess, and lower the burden of irreversible complications.
Her remarks also fit the current arc of endocrinology, where targeted therapies are becoming more common and more biologically precise. Treatment is increasingly built around receptor signaling, tissue selectivity, and disease-specific pathways rather than broad endocrine suppression. In acromegaly, for example, Nachtigall cited paltusotine, an oral therapy that works well in tumors expressing somatostatin receptor type 2 (SST2). For hypothalamic obesity, she pointed to setmelanotide, which targets the melanocortin-4 receptor (MC4R). Both drugs illustrate how receptor biology is now translating into practical, phenotype-driven treatment.
New endocrine drugs arrive with a familiar access problem
The therapeutic momentum in endocrinology is real, and so is the friction that surrounds it.
Nachtigall was direct about the barrier that now shadows many promising drugs: expense, insurance restrictions, and the administrative drag of prior authorization. For specialty practices, this is not a minor inconvenience. It can delay initiation of treatment, create uncertainty for patients who are already managing a chronic disease, and add hours of work for clinicians and staff who must document medical necessity in detail.
She described a practical workaround in her own practice: a designated full-time staff member who handles prior authorizations. That single operational choice can change how quickly patients receive therapy, especially when the medication is high-cost and the approval process is complex. In endocrine care, where many treatments are long-term and disease-specific, administrative access can shape clinical success as much as receptor affinity or pharmacokinetics.
The tension is especially visible in disorders such as acromegaly, where effective control depends on sustained treatment and follow-up. A therapy that is pharmacologically sound but inaccessible remains clinically incomplete. For patients, the delay is not abstract; it can mean ongoing symptom burden, continued exposure to hormone excess, and prolonged uncertainty about whether the disease is truly controlled.
Patient education and mentorship have become part of the therapeutic model
Nachtigall’s influence extends beyond direct care. She has organized educational programs for patients with acromegaly, served on multiple Endocrine Society committees and task forces, and co-founded a visiting scholars program designed to introduce trainees to endocrinology early. That mix of patient-facing education and professional mentorship reflects a field that depends heavily on communication, continuity, and exposure to uncommon disease.
Her approach to recruiting future endocrinologists is notably restrained. Rather than trying to persuade students outright, she opens a window into real practice at a pituitary center and lets the work speak for itself. The appeal lies in the patient stories, the multidisciplinary model, and the intellectual movement from bedside to bench and back again. A student who once thought she wanted emergency medicine ultimately pivoted toward endocrinology after recognizing the value of long-term relationships with patients who are known over many years. That is a familiar pattern in a specialty where diagnostic detective work and follow-up often matter as much as procedural urgency.
The visiting scholars program also operates on several levels. One branch brings in international students and physicians interested in the pituitary field. Another offers Harvard medical students an advanced neuroendocrine clerkship. The most distinctive track reaches even earlier, welcoming students from the second year of college through medical school. Some participants have gone on to endocrinology or related fields, a sign that early exposure can shape career choices before training paths become fixed.
Professional societies still matter in a field built on expertise and access
For Nachtigall, the Endocrine Society has served as both classroom and career scaffold. She recalled giving her first oral presentation as a fellow in 1996 and described the annual meetings as places where education, scientific rigor, and professional connection meet in the same room. After three decades of attending ENDO meetings, she still sees value in the exchange of ideas and the chance to learn from colleagues beyond her home institution.
That role is especially important in endocrinology, where expertise is distributed across high-volume centers, academic programs, and community practices, yet the patient population often includes rare disorders that require specialized knowledge. Societies create a common reference point for standards, education, and peer support. They also give clinicians at every stage of training access to mentors and collaborators who can shape practice in concrete ways.
Nachtigall described the organization as a place committed to excellence, fairness, and integrity. For a specialty built on careful diagnosis and prolonged treatment, those qualities are not abstract ideals. They are the infrastructure of better care.
Her award, then, is less a celebration of one breakthrough than a recognition of what endocrine practice looks like at its best: careful diagnosis, biologically informed therapy, patient education, and the persistence required to keep treatment moving when access barriers slow everything down.